A New TNM Staging Strategy for Node-Positive (Stage III) Colon Cancer

Greene, Frederick L.; Stewart, Andrew K.; Norton, H. James

doi:10.1097/00000658-200210000-00003

Cited by 216 publications

(143 citation statements)

References 16 publications

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…Although histological grading plays a significant role in disease prognosis (Greene et al, 2002), it is not part of the TNM classification (Compton et al, 2002). Our study also demonstrates a high correlation between tumor grading and recurrence (p<0.008).…”

Section: Discussionmentioning

confidence: 55%

Prevalence of Local Recurrence of Colorectal Cancer at the Iranian Cancer Institute

Omranipour

Mahmoodzadeh²,

Safavi³

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 55%

Prevalence of Local Recurrence of Colorectal Cancer at the Iranian Cancer Institute

Omranipour

Mahmoodzadeh²,

Safavi³

2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Scheithauer et al 182 Cochrane Database 183 Saltz et al 120 and de Gramont et al 131 Goldberg et al 135 and Fuchs et al 121 Hurwitz et al 146 Tumor invades submucosa T 2 Tumor invades muscularis propia T 3 Tumor invades through the muscularis propria into the subserosa T 4 Tumor directly invades other organs or structures, or perforates visceral Peritoneum Regional lymph nodes (N) N x…”

Section: Adapted With Permission From Meyerhardt and Mayer 31mentioning

confidence: 99%

Systemic Treatment of Colorectal Cancer

2008

View full text Add to dashboard Cite

Colorectal cancer is the fourth most common non-cutaneous malignancy in the United States and the second most frequent cause of cancer-related death. Over the past 12 years, significant progress has been made in the systemic treatment of this malignant condition. Six new chemotherapeutic agents have been introduced, increasing median overall survival for patients with metastatic colorectal cancer from less than 9 months with no treatment to approximately 24 months. For patients with stage III (lymph node positive) colon cancer, an overall survival benefit for fluorouracil-based chemotherapy has been firmly established, and recent data have shown further efficacy for the inclusion of oxaliplatin in such adjuvant treatment programs. For patients with stage II colon cancer, the use of adjuvant chemotherapy remains controversial, but may be appropriate in a subset of individuals at higher risk for disease recurrence. Ongoing randomized clinical trials are evaluating how best to combine currently available therapies, while smaller studies are evaluating new agents, with the goal of continued progress in prolonging life among patients with metastatic colorectal cancer and increasing cure rates among those with resectable disease.

show abstract

“…When patients have a similar number of lymph node resections, a higher number of lymph nodes involved is associated with inferior survival and worse outcomes [4,5]. Furthermore, Aldecoa et al showed that higher molecular lymph node tumor burden in grossly negative lymph node cancer (Stage I–II) is associated with inferior prognosis [6].…”

Section: Introductionmentioning

confidence: 99%

Factors associated with short recurrence-free survival in completely resected colon cancer

Alnimer

Ghamrawi

Aburahma

et al. 2017

Journal of Community Hospital Internal Medicine Perspectives

View full text Add to dashboard Cite

Background: Several factors could affect disease recurrence in surgically resected colon cancer. While the role of certain factors such as cancer stage and grade is well established, the role of other factors (e.g., histological subtypes) is yet to be determined. Objective:Therefore, we conducted a study to evaluate the impact of several factors in recurrence-free survival (RFS) in patients who were disease free following surgical resection of the colon cancer. Design/Methods: Data were collected for patients with Stage I–III colon cancer who underwent complete surgical resection of the tumor between January 2010 and December 2015 in our institution. A total of 90 subjects met the inclusion criteria and were included in the study. The following factors were collected at the time of surgical resection of the colonic tumor: patient’s age, gender, colon cancer stage, grade and histological subtype, body mass index, hemoglobin A1c, and smoking history. Results: A total of 28 patients (31%) developed recurrence and had a mean follow-up time of 19.8 months (range: 2–54.4 months). Median RFS was 54.4 months with a 5-year RFS of 49%. Advanced colonic cancer stage and mucinous histological subtype were associated with shorter RFS with an HR of 2.37, 95% CI = 1.38–4.06, and 95% CI = 1.02–5.90, respectively. Current smokers or those who quit less than 15 years earlier tended to have worse RFS with an HR of 2.47, 95% CI = 0.98–6.27. Conclusion: Advanced colon cancer stage and mucinous histological subtype are independent risk factors for cancer recurrence and shorter RFS in completely resected colonic tumor.

show abstract

A New TNM Staging Strategy for Node-Positive (Stage III) Colon Cancer

Cited by 216 publications

References 16 publications

Prevalence of Local Recurrence of Colorectal Cancer at the Iranian Cancer Institute

Prevalence of Local Recurrence of Colorectal Cancer at the Iranian Cancer Institute

Systemic Treatment of Colorectal Cancer

Factors associated with short recurrence-free survival in completely resected colon cancer

Contact Info

Product

Resources

About